1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

GlobalData estimated that prescription drug sales for IBS were approximately $4.0m in France in 2013. Ironwood/Actavis/Almirall/Astellas’ Linzess is the only available product indicated for IBS-C in Germany, which was launched in 2013. Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan and antidepressants are used off-label for the management of IBS patients in Italy. Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan and antidepressants are used off-label for the management of IBS patients in Spain. Ironwood/Actavis/Almirall/Astellas’ Linzess is the only available product indicated for IBS-C in the UK, which was launched in 2013.

Scope

- Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Irritable Bowel Syndrome

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Irritable Bowel Syndrome
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the 5EU

Table Of Contents

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.2 Classification 15
3.3 Symptoms 16
3.4 Prognosis 17
3.5 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 22
4.2 France 24
4.3 Germany 27
4.4 Italy 29
4.5 Spain 31
4.6 UK 33
5 Competitive Assessment 35
5.1 Overview 35
5.2 Product Profiles - Major Brands, IBS-C 36
5.2.1 Linzess (linaclotide) 36
5.3 Product Profiles - Major Brands, Other 43
5.3.1 Antidepressants 43
5.4 Other Therapeutic Classes 47
6 Unmet Need and Opportunity 49
6.1 Overview 49
6.2 More Effective Pharmacotherapies 50
6.2.1 Unmet Need 50
6.2.2 Gap Analysis 51
6.2.3 Opportunity 52
6.3 Therapies for the IBS-D Subtype 52
6.3.1 Unmet Need 52
6.3.2 Gap Analysis 53
6.3.3 Opportunity 53
6.4 Therapies for the IBS-M Subtype 53
6.4.1 Unmet Need 53
6.4.2 Gap Analysis 54
6.4.3 Opportunity 54
6.5 Therapies to Address Abdominal Pain and Bloating Symptoms 54
6.5.1 Unmet Need 54
6.5.2 Gap Analysis 55
6.5.3 Opportunity 55
6.6 Improved Diagnosis Rate for IBS 55
6.6.1 Unmet Need 55
6.6.2 Gap Analysis 56
6.6.3 Opportunity 56
7 Pipeline Assessment 57
7.1 Overview 57
7.2 Promising Drugs in Clinical Development 57
7.3 Product Profiles - Late-Stage Pipeline, IBS-D 59
7.3.1 Eluxadoline 59
7.3.2 Ibodutant (MEN-15596) 66
7.3.3 Xifaxan (rifaximin) 71
7.4 Product Profiles - Late-Stage Pipeline, IBS-C 79
7.4.1 Plecanatide 79
7.4.2 Tenapanor (AZD1722, RDX5791) 84
7.5 Other Drugs in Development for IBS 88
8 Market Outlook 89
8.1 Global Markets 89
8.1.1 Drivers and Barriers - Global Issues 89
8.2 France 90
8.2.1 Forecast 90
8.2.2 Key Events 94
8.2.3 Drivers and Barriers 94
8.3 Germany 96
8.3.1 Forecast 96
8.3.2 Key Events 100
8.3.3 Drivers and Barriers 100
8.4 Italy 102
8.4.1 Forecast 102
8.4.2 Key Events 106
8.4.3 Drivers and Barriers 106
8.5 Spain 108
8.5.1 Forecast 108
8.5.2 Key Events 111
8.5.3 Drivers and Barriers 111
8.6 UK 113
8.6.1 Forecast 113
8.6.2 Key Events 117
8.6.3 Drivers and Barriers 117
9 Appendix 120
9.1 Bibliography 120
9.2 Abbreviations 125
9.3 Methodology 128
9.4 Forecasting Methodology 128
9.4.1 Diagnosed IBS Patients 128
9.4.2 Drugs Included in Each Therapy Type 129
9.4.3 Launch and Patent Expiry Dates 129
9.4.4 General Pricing Assumptions 130
9.4.5 Individual Drug Assumptions 130
9.4.6 Generic Erosion 131
9.4.7 Pricing of Pipeline Agents 131
9.5 Primary Research - KOLs Interviewed for This Report 133
9.6 Primary Research - Prescriber Survey 135
9.7 About the Authors 136
9.7.1 Analyst 136
9.7.2 Therapy Area Director 136
9.7.3 Global Head of Healthcare 137
9.8 About GlobalData 138
9.9 Disclaimer 138

1.1 List of Tables

Table 1: Common Symptoms of IBS 16
Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS 19
Table 3: Treatment Guidelines for IBS 21
Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 5EU, 2014† 22
Table 5: IBS Diagnosis and Treatment, Country Profile - France 26
Table 6: IBS Diagnosis and Treatment, Country Profile - Germany 28
Table 7: IBS Diagnosis and Treatment, Country Profile - Italy 30
Table 8: IBS Diagnosis and Treatment, Country Profile - Spain 32
Table 9: IBS Diagnosis and Treatment, Country Profile - UK 34
Table 10: Leading Branded Treatments for IBS, 2014 36
Table 11: Product Profile - Linzess 38
Table 12: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks 40
Table 13: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks 40
Table 14: Safety of Linzess - Most Frequently Reported Adverse Events 42
Table 15: Linzess SWOT Analysis, 2014 43
Table 16: Use of Antidepressants in IBS, SWOT Analysis, 2014 47
Table 17: Summary of Other Therapeutic Classes of Pharmacologics in IBS, 2014 48
Table 18: Unmet Needs and Opportunities in IBS 50
Table 19: Drugs in Late-Stage Clinical Development for IBS, 2014 59
Table 20: Product Profile - Eluxadoline 60
Table 21: Eluxadoline SWOT Analysis, 2014 66
Table 22: Product Profile - Ibodutant 68
Table 23: Ibodutant SWOT Analysis, 2014 71
Table 24: Product Profile - Xifaxan 74
Table 25: Safety of Xifaxan - Most Frequently Reported Adverse Events 77
Table 26: Xifaxan SWOT Analysis, 2014 79
Table 27: Product Profile - Plecanatide 81
Table 28: Plecanatide SWOT Analysis, 2014 84
Table 29: Product Profile - Tenapanor 85
Table 30: Tenapanor SWOT Analysis, 2014 87
Table 31: Drugs in Early-Stage Clinical Development for IBS, 2014 88
Table 32: Global IBS Market - Drivers and Barriers, 2013-2023 89
Table 33: Sales Forecasts ($m) for IBS in France, 2013-2023 92
Table 34: Key Events Impacting Sales for IBS in France, 2013-2023 94
Table 35: IBS Market in France - Drivers and Barriers, 2013-2023 94
Table 36: Sales Forecasts ($m) for IBS in Germany, 2013-2023 98
Table 37: Key Events Impacting Sales for IBS in Germany, 2013-2023 100
Table 38: IBS Market in Germany - Drivers and Barriers, 2013-2023 100
Table 39: Sales Forecasts ($m) for IBS in Italy, 2013-2023 104
Table 40: Key Events Impacting Sales for IBS in Italy, 2013-2023 106
Table 41: IBS Market in Italy - Drivers and Barriers, 2013-2023 106
Table 42: Sales Forecasts ($m) for IBS in Spain, 2013-2023 109
Table 43: Key Events Impacting Sales for IBS in Spain, 2013-2023 111
Table 44: IBS Market in Spain - Drivers and Barriers, 2013-2023 111
Table 45: Sales Forecasts ($m) for IBS in the UK, 2013-2023 115
Table 46: Key Events Impacting Sales for IBS in the UK, 2013-2023 117
Table 47: IBS Market in the UK - Drivers and Barriers, 2013-2023 117
Table 48: Key Launch Dates 129
Table 49: Key Patent Expiries 129
Table 50: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 135

1.2 List of Figures

Figure 1: Summary of Pharmacotherapies Used to Treat IBS 24
Figure 2: IBS - Phase IIb-III Pipeline, October 2014 58
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023 58
Figure 4: Clinical and Commercial Positioning of Eluxadoline 65
Figure 5: Clinical and Commercial Positioning of Ibodutant 70
Figure 6: Clinical and Commercial Positioning of Xifaxan 78
Figure 7: Clinical and Commercial Positioning of Plecanatide 83
Figure 8: Clinical and Commercial Positioning of Tenapanor 87
Figure 9: Sales for IBS in France by Therapy Type, 2013-2023 93
Figure 10: Sales for IBS in Germany by Therapy Type, 2013-2023 99
Figure 11: Sales for IBS in Italy by Therapy Type, 2013-2023 105
Figure 12: Sales for IBS in Spain by Therapy Type, 2013-2023 110
Figure 13: Sales for IBS in the UK by Therapy Type, 2013-2023 116

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.